Aurobindo Pharma (AUROPHARMA.NS)

Overall impact
C (59)

Commentary

Aurobindo Pharma is an average overall performer. With a 'C' rating of 59.5 for overall impact (61st percentile compared to all companies), Aurobindo Pharma ranks 111th out of 154 industry peers, behind Adamis Pharmaceuticals, Benitec Biopharma, Aquinox Pharmaceuticals and 107 others, and ahead of Evolus, Oyster Point Pharma, Lupin and 40 others. On top material causes for Aurobindo Pharma's industry (Pharmaceuticals & Biotech), Aurobindo Pharma performs well in Technology Innovation (91.1 score), Disease Eradication (81.1) and Decent, Safe Work Opportunities (81.8) and performs poorly in Reduced Waste (36.5 score), Child and Maternal Health (39.0), Sustainable Use of Water (37.4) and 3 other causes where it received a 'D' or 'F' score.
Impact
Cause AUROPHARMA.NS
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Employees
29,209
Sector
Health Care
Industry
Pharmaceuticals
Sub-industry
Pharmaceuticals
SASB industry
Biotechnology & Pharmaceuticals
Headquarters
India
Share classes
AUROPHARMA.NS
Description
Aurobindo Pharma Limited, a biopharmaceutical company, engages in the manufacture of generic formulations and active pharmaceutical ingredients in India, the United States of America, Europe, Puerto Rico, and internationally. The company offers formulation in form of oral solids, liquids, injectables, and vaccines, as well as over-the-counter drugs; and active pharmaceutical ingredients (APIs), biosimilars, biocatalysts, peptides, and hormones targeting key therapeutic areas, including central nervous system, cardiovascular, respiratory, antibiotics, anti-retroviral, anti-diabetics, gastroenterology, oncology, and dermatology. It also provides antiretroviral drugs for the people and children living with HIV; and provides project-based chemistry contract services that cover the clinical stage through to manufacturing and management of the entire drug lifecycle in the API space for sterile and non-sterile penicillin's, cephalosporins, penems, and non-beta lactams. The company was incorporated in 1986 and is headquartered in Hyderabad, India.
Material causes
Ethos considers the following causes material for Aurobindo Pharma, based on its industry sub-industry Pharmaceuticals. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.